BR0111667A - Novos compostos - Google Patents

Novos compostos

Info

Publication number
BR0111667A
BR0111667A BR0111667-3A BR0111667A BR0111667A BR 0111667 A BR0111667 A BR 0111667A BR 0111667 A BR0111667 A BR 0111667A BR 0111667 A BR0111667 A BR 0111667A
Authority
BR
Brazil
Prior art keywords
new compounds
compounds
therapies
new
formula
Prior art date
Application number
BR0111667-3A
Other languages
English (en)
Inventor
Eriksson Tomas
Tomas Klingstedt
Tesfaledet Mussie
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0002331A external-priority patent/SE0002331D0/xx
Priority claimed from SE0004480A external-priority patent/SE0004480D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0111667A publication Critical patent/BR0111667A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"NOVOS COMPOSTOS". A presente invenção proporciona compostos de fórmula geral (I): em que m, n, Q, Z^ 1^ Z^ 2^, R^ 1^, R^ 2^, R^ 3^, R^ 4^, R^ 5^, R^ 6^,R^ 7^ e R^ 8^ são como definidos no relatório descritivo, e ainda processos para sua preparação, composições farmacêuticas contendo os referidos compostos e seu uso em terapias.
BR0111667-3A 2000-06-20 2001-06-14 Novos compostos BR0111667A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0002331A SE0002331D0 (sv) 2000-06-20 2000-06-20 Novel compounds
SE0004480A SE0004480D0 (sv) 2000-12-05 2000-12-05 Novel compounds
PCT/SE2001/001377 WO2001098273A1 (en) 2000-06-20 2001-06-14 Novel compounds

Publications (1)

Publication Number Publication Date
BR0111667A true BR0111667A (pt) 2003-05-13

Family

ID=26655154

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111667-3A BR0111667A (pt) 2000-06-20 2001-06-14 Novos compostos

Country Status (22)

Country Link
US (3) US6911458B2 (pt)
EP (1) EP1299357A1 (pt)
JP (1) JP4022142B2 (pt)
KR (1) KR100799061B1 (pt)
CN (1) CN1307157C (pt)
AR (1) AR028948A1 (pt)
AU (2) AU7476301A (pt)
BR (1) BR0111667A (pt)
CA (1) CA2414095C (pt)
CZ (1) CZ20024146A3 (pt)
EE (1) EE05157B1 (pt)
HU (1) HUP0301187A3 (pt)
IL (2) IL153167A0 (pt)
IS (1) IS6658A (pt)
MX (1) MXPA02012425A (pt)
MY (1) MY136520A (pt)
NO (1) NO324698B1 (pt)
NZ (1) NZ523047A (pt)
PL (1) PL203936B1 (pt)
RU (2) RU2298550C2 (pt)
SK (1) SK17932002A3 (pt)
WO (1) WO2001098273A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
US7005439B2 (en) * 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
AR035230A1 (es) * 2001-03-19 2004-05-05 Astrazeneca Ab Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
PL378559A1 (pl) * 2003-02-17 2006-05-02 F. Hoffmann-La Roche Ag Pochodne piperydynobenzenosulfonoamidu
US8796436B2 (en) 2003-04-17 2014-08-05 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
JP4597976B2 (ja) 2003-04-17 2010-12-15 アルナイラム ファーマシューティカルズ インコーポレイテッド 修飾ｉＲＮＡ剤
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
US7732442B2 (en) 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
SE0303090D0 (sv) 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
SE0303541D0 (sv) 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
JP2009503063A (ja) * 2005-08-01 2009-01-29 アストラゼネカ・アクチエボラーグ 呼吸器疾患の処置に有用なケモカイン受容体モジュレーターとしての新規ピペリジン誘導体
TW200734305A (en) * 2005-08-02 2007-09-16 Astrazeneca Ab New salt III
TW200738635A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
TW200800895A (en) * 2005-11-02 2008-01-01 Astrazeneca Ab Novel compounds
JP2009529038A (ja) * 2006-03-07 2009-08-13 アストラゼネカ・アクチエボラーグ ピペリジン誘導体、それらの製造法、治療剤としてのそれらの使用およびそれらを含む医薬組成物
US20090197914A1 (en) * 2006-03-07 2009-08-06 Peter Cage Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them
US20080064884A1 (en) * 2006-05-10 2008-03-13 Astrazeneca Ab Novel Process 1
WO2008010764A2 (en) * 2006-07-18 2008-01-24 Astrazeneca Ab A process for the preparation of substituted 2-acetylamino-alkoxyphenyl
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
WO2008103125A1 (en) * 2007-02-23 2008-08-28 Astrazeneca Ab Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma
WO2008121065A1 (en) * 2007-03-30 2008-10-09 Astrazeneca Ab Novel pyrrolidine derivatives as antagonists of the chemokine receptor
WO2008128996A1 (en) 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
ES2393818T3 (es) 2007-04-23 2012-12-28 Janssen Pharmaceutica, N.V. Derivados de tipo 4-alcoxipiridazina como antagonistas de los receptores 2 de la dopamina de disociación rápida
AU2009266001B2 (en) 2008-07-03 2014-03-27 Janssen Pharmaceutica Nv Substituted 6- (1-piperazinyl) -pyridazines as 5-HT6 receptor antagonists
SI2307374T1 (sl) 2008-07-31 2017-05-31 Janssen Pharmaceutica Nv Piperazin-1-il-trifluorometil-substituirani-piridini kot hitro disociirajoči antagonisti receptorja dopamin 2
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
EP3083609B1 (en) 2013-12-19 2018-08-15 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US11958818B2 (en) 2019-05-01 2024-04-16 Boehringer Ingelheim International Gmbh (R)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
EP4115885A1 (en) 2021-07-05 2023-01-11 Charité - Universitätsmedizin Berlin A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1220440B (de) 1962-02-14 1966-07-07 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von Derivaten des 1-(o-Bromphenoxy)-2-hydroxy-3-amino-propans und deren Saeureadditionssalzen
US3577432A (en) * 1968-12-23 1971-05-04 Robins Co Inc A H 1-substituted-3-phenoxypyrrolidines
US4029801A (en) 1970-09-03 1977-06-14 John Wyeth & Brother Limited Pharmaceutical compositions and methods of treating hypertension
JPS5511670B1 (pt) 1971-07-13 1980-03-26
US4080328A (en) * 1971-07-13 1978-03-21 Sumitomo Chemical Company, Limited N-substituted heterocyclic derivatives and preparation thereof
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
US3755584A (en) * 1972-04-03 1973-08-28 Abbott Lab Tranquilizers
SE378109B (pt) * 1972-05-19 1975-08-18 Bofors Ab
FR2190430A1 (en) 1972-06-29 1974-02-01 Ferlux N-aminomethylhydroxamic acids - with antiinflammatory activity pre-pared by Mannich reaction
US3894030A (en) 1973-01-04 1975-07-08 Janssen Pharmaceutica Nv 1-{8 1-(2-Hydroxy-3-aryloxypropyl)-4-piperidyl{9 -2-benzimidazolinones and related compounds
US3818017A (en) 1973-01-04 1974-06-18 Janssen Pharmaceutica Nv 1-{8 1-(2-hydroxy-3-aryloxypropyl)-4-piperidyl{9 -2-benzimidazolinones and related compounds
US4166119A (en) * 1978-04-14 1979-08-28 American Hoechst Corporation Analgesic and tranquilizing spiro[dihydrobenzofuran]piperidines and pyrrolidines
WO1980000152A1 (en) * 1978-07-03 1980-02-07 Sandoz Ag 3-aminopropoxy-aryl derivates,preparation and use thereof
US4264613A (en) 1979-08-01 1981-04-28 Science Union Et Cie, Societe Francaise De Recherche Medicale Piperidylbenzimidazolinone compounds
FR2469411A1 (fr) 1979-11-15 1981-05-22 Science Union & Cie Nouveaux derives de la piperidylbenzimidazolinone, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
EP0095454A3 (de) 1982-05-13 1985-04-03 Gerot-Pharmazeutika Gesellschaft m.b.H. Neue kernsubstituierte Pyrogallol-Derivate
JPS59222484A (ja) 1983-06-02 1984-12-14 Kowa Co テトラヒドロナフチルカルボン酸フエニルエステル誘導体
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US5614533A (en) * 1987-03-13 1997-03-25 Bio-Mega/Boehringer Ingelheim Research, Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
DE3723568C2 (de) 1987-07-16 1994-01-27 Siemens Ag Differenzstromschutzschalter
DE3723648A1 (de) 1987-07-17 1989-01-26 Sandoz Ag Indol-derivate, ihre herstellung und sie enthaltende arzneimittel
AU4414289A (en) * 1988-09-30 1990-04-18 Mallinckrodt, Inc. A process for the production of granular metal soaps
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9003057D0 (sv) 1990-09-26 1990-09-26 Astra Ab New process
ES2027897A6 (es) 1991-01-24 1992-06-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de la difenilmetilpiperacina.
IL105716A0 (en) 1992-06-08 1993-09-22 Richter Gedeon Vegyeszet Aminopropanol derivatives,their preparation and pharmaceutical compositions containing them
ZA935697B (en) 1992-08-07 1994-03-10 Sankyo Co Peptides capable of inhibiting the activity of hiv protease their preparation and their therapeutic use
US5614523A (en) * 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5741789A (en) * 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5789402A (en) * 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US6184225B1 (en) 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE19703131A1 (de) 1997-01-29 1998-07-30 Bayer Ag Verwendung von Chinoxalin in Dreier-Kombination mit Protease-Inhibitoren und Reverse Transkriptaseinhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
EP1535909A3 (en) 1997-11-18 2005-07-13 Teijin Limited Cyclic amine derivatives and their use as drugs
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
FR2780057B1 (fr) 1998-06-18 2002-09-13 Sanofi Sa Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2351631A1 (en) 1998-11-20 2000-06-02 F. Hoffmann-La Roche Ag Piperidine quaternary salts-ccr-3 receptor antagonists
AU2482100A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1140086A4 (en) 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SE9900833D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
AU2942000A (en) 1999-03-11 2000-09-28 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivatives
JP3495955B2 (ja) * 1999-03-26 2004-02-09 シャープ株式会社 半導体メモリ装置及びその製造方法
KR20010108394A (ko) 1999-03-26 2001-12-07 다비드 에 질레스 신규 화합물
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
ATE277903T1 (de) 1999-05-14 2004-10-15 Bristol Myers Squibb Pharma Re Zyklische aminderivate und ihre verwendung
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
AUPQ165599A0 (en) 1999-07-15 1999-08-05 University Of Sydney, The Optical processing method and apparatus and products thereof
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
DE60033964T2 (de) 1999-12-17 2007-11-29 Sanofi-Aventis Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung
FR2802533B1 (fr) 1999-12-17 2002-02-15 Sanofi Synthelabo Phenoxypropanolamines, leur preparation et leur application en therapeutique
CO5300399A1 (es) * 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
CN1431999A (zh) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
AR028947A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US7005439B2 (en) * 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
JP2004516238A (ja) 2000-06-21 2004-06-03 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー ケモカイン受容体活性調節剤としてのｎ−ウレイドアルキル−ピペリジン
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
DK1305329T4 (da) 2000-08-05 2015-06-15 Glaxo Group Ltd 6alpha, 9alpha-difluor-17alpha-(2-furanylcarboxyl)oxy-11beta-hydroxy-16alpha-methyl-3-oxo-androst-1,4-dien-17-carbothiosyre-S-fluormethylester som et antiinflammatorisk middel
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
GB2373186A (en) 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
AR035230A1 (es) * 2001-03-19 2004-05-05 Astrazeneca Ab Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
DE60224172T2 (de) 2001-03-22 2008-12-04 Glaxo Group Ltd., Greenford Formanilid-derivative als beta2-adrenorezeptor-agonisten
SE0101038D0 (sv) * 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
KR100406536B1 (ko) * 2001-03-28 2003-11-20 주식회사 하이닉스반도체 산소확산방지막으로서 알루미늄 산화막을 구비하는강유전체 메모리 소자 및 그 제조 방법
GB0108046D0 (en) 2001-03-30 2001-05-23 Astrazeneca Ab Chemical compounds
EP1389616B1 (en) 2001-04-27 2011-07-27 Mitsubishi Tanabe Pharma Corporation 3,4-Dihalobenzylpiperidine derivatives and their medical use
BR0209271A (pt) 2001-04-30 2004-06-15 Glaxo Group Ltd Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto
US6730951B2 (en) * 2001-06-25 2004-05-04 Matsushita Electric Industrial Co., Ltd. Capacitor, semiconductor memory device, and method for manufacturing the same
JP4467229B2 (ja) * 2001-09-12 2010-05-26 株式会社ハイニックスセミコンダクター 半導体素子の製造方法
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
GB0127547D0 (en) 2001-11-16 2002-01-09 Astrazeneca Ab Chemical compounds
SE0104251D0 (sv) 2001-12-14 2001-12-14 Astrazeneca Ab Novel compounds
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
US6583507B1 (en) * 2002-04-26 2003-06-24 Bum Ki Moon Barrier for capacitor over plug structures
CA2499314C (en) 2002-10-11 2010-08-24 Pfizer Inc. Indole derivatives as beta-2 agonists
KR100578212B1 (ko) * 2003-06-30 2006-05-11 주식회사 하이닉스반도체 엠티피 구조의 강유전체 캐패시터 및 그 제조 방법
US7180141B2 (en) * 2004-12-03 2007-02-20 Texas Instruments Incorporated Ferroelectric capacitor with parallel resistance for ferroelectric memory
JP2009503063A (ja) * 2005-08-01 2009-01-29 アストラゼネカ・アクチエボラーグ 呼吸器疾患の処置に有用なケモカイン受容体モジュレーターとしての新規ピペリジン誘導体
TW200734305A (en) * 2005-08-02 2007-09-16 Astrazeneca Ab New salt III
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt

Also Published As

Publication number Publication date
HUP0301187A3 (en) 2010-03-29
EP1299357A1 (en) 2003-04-09
SK17932002A3 (sk) 2003-09-11
NO20026064L (no) 2003-02-17
AU2001274763B2 (en) 2006-10-05
NO20026064D0 (no) 2002-12-17
EE05157B1 (et) 2009-04-15
PL203936B1 (pl) 2009-11-30
CN1307157C (zh) 2007-03-28
JP4022142B2 (ja) 2007-12-12
US7528156B2 (en) 2009-05-05
WO2001098273A1 (en) 2001-12-27
US20030162772A1 (en) 2003-08-28
US6911458B2 (en) 2005-06-28
CZ20024146A3 (cs) 2003-05-14
HUP0301187A2 (hu) 2003-08-28
IL153167A0 (en) 2003-07-31
AR028948A1 (es) 2003-05-28
RU2298550C2 (ru) 2007-05-10
MY136520A (en) 2008-10-31
NZ523047A (en) 2004-09-24
KR20030017548A (ko) 2003-03-03
JP2004507461A (ja) 2004-03-11
CN1476434A (zh) 2004-02-18
RU2419608C2 (ru) 2011-05-27
EE200200704A (et) 2004-08-16
IL153167A (en) 2009-06-15
RU2006141320A (ru) 2008-06-10
MXPA02012425A (es) 2003-04-25
CA2414095C (en) 2009-01-06
US20090306141A1 (en) 2009-12-10
AU7476301A (en) 2002-01-02
NO324698B1 (no) 2007-12-03
CA2414095A1 (en) 2001-12-27
IS6658A (is) 2002-12-17
PL366198A1 (en) 2005-01-24
US20050090494A1 (en) 2005-04-28
KR100799061B1 (ko) 2008-01-29

Similar Documents

Publication Publication Date Title
BR0111667A (pt) Novos compostos
BR0108678A (pt) Novos compostos
BR0312560A (pt) Novas espiropiperidinas ou espiropirrolidinas tricìclicas
SE9904505D0 (sv) Novel compounds
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BRPI0407734A (pt) derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
BR9911013A (pt) Derivados de pirazol como inibidores da p-38 map quinase
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
BR0213877A (pt) Compostos orgânicos
BR0014225A (pt) Derivados de pirazol
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
BR0310077A (pt) Novos compostos e sua utilização
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
BRPI0113162B8 (pt) compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos
SE0104251D0 (sv) Novel compounds
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BR0307461A (pt) Derivados de quinazolinona e seu uso como agonistas de cb
BR0012610A (pt) Novo derivado de difenilpiperidina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements